Trimodal (18)F-choline-PET/mpMRI/TRUS Targeted Prostate Biopsies
NCT: NCT02971995 · TERMINATED
Brief Summary
Prostate cancer is the first cancer in humans (25%). The most widely used tracer in oncology, the 18-Fluoro DeoxyGlucose does not allow the study of prostatic neoplasia. On the other hand, Choline, which is an amino alcohol, is involved in the synthesis of cell membranes and has an affinity for prostate cells. Its concentration is directly proportional to cell proliferation. The analogue of choline has the advantage of having a rapid and stable accumulation over time in cancer cells, with a rapid urinary excretion (4 minutes after injection). The goal of this study is to assess the feasibility and the accuracy for targeting image guided prostate biopsy to detect prostate cancer after Imaging fusion of choline-PET/CT compared to 1.5T multiparametric magnetic resonance imaging (mpMRI) with 3D-transrectal ultrasound (TRUS) .
Frequently Asked Questions
What is Trimodal (18)F-choline-PET/mpMRI/TRUS Targeted Prostate Biopsies?
Trimodal (18)F-choline-PET/mpMRI/TRUS Targeted Prostate Biopsies is a clinical trial registered under NCT02971995. Current status: TERMINATED.
What is the status of NCT02971995?
The current status of NCT02971995 (Trimodal (18)F-choline-PET/mpMRI/TRUS Targeted Prostate Biopsies) is: TERMINATED.
When did Trimodal (18)F-choline-PET/mpMRI/TRUS Targeted Prostate Biopsies start?
Trimodal (18)F-choline-PET/mpMRI/TRUS Targeted Prostate Biopsies started on 2014-12.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.